Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

Care of patients with systemic immunoglobulin light chain (AL) amyloidosis has undergone transformative changes, leading to marked, steady progress in outcomes for patients over the past four decades.

Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...

How Nuclear Cardiology Transformed Patient Care in Cardiac Amyloidosis, and What the Remarkable Developments in the Field Have Taught Us Developments have unfolded in cardiac amyloidosis, ... where we ...

Wainua (eplontersen) is a prescription injection medicine that slows down nerve damage in people with a type of amyloidosis called hereditary transthyretin-mediated amyloidosis (hATTR). The FDA ...

Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...

It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who had their ...

While still considered a rare disease, transthyretin amyloid cardiomyopathy (ATTR-CM) is nevertheless emerging in more people than previously thought due to increased interest and improved access to ...

The Amyloidosis Program at University of Utah Health and Huntsman Cancer Institute is one of the few programs in the United States specifically designed to treat amyloidosis and provide ...

Multiple myeloma and amyloidosis begin the same way – in plasma cells, white blood cells that help your immune system. But multiple myeloma (MM) is a rare blood cancer while amyloidosis is a buildup ...